SCHEMBL5197844

SCHEMBL5197844

COCCC1(N)CCC(N)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL28637308 0.84 PRKCA (0.31)
SCHEMBL16110280 0.82
SCHEMBL16109130 0.78
SCHEMBL636866 0.76 GNAI3 (0.31)
SCHEMBL22190739 0.75 DPP4 (0.33)
SCHEMBL28688162 0.72
SCHEMBL28031284 0.72 GNAI3 (0.37)
SCHEMBL21855942 0.72
SCHEMBL8763507 0.71
SCHEMBL30890403 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4090159-A1 PYRAZOLYLPYRIMIDINES AND USE THEREOF Biotheryx, Inc. (US) 2022-11-23 EP claimed
EP-1773796-A2 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-18 EP claimed
WO-2006021655-A2 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-03-02 WO claimed
CN-118076581-A Iron death modulators, their preparation and use 维泰瑞隆有限公司 2024-05-24 CN disclosed
EP-4090159-A1 PYRAZOLYLPYRIMIDINES AND USE THEREOF Biotheryx, Inc. (US) 2022-11-23 EP disclosed
CN-108727363-B Novel cyclin dependent kinase CDK9 inhibitor 劲方医药科技(上海)有限公司 2020-06-19 CN disclosed
CN-108727363-A A kind of novel cell cyclin-dependent kinase CDK9 inhibitor 上海炯烁医药科技有限公司 2018-11-02 CN disclosed